Related Experiment Videos
Immunologically defined prognostic subgroups as predictors of response to BCG immunotherapy
Summary
This study explored immunotherapy for non-small cell lung cancer. BCG immunotherapy showed a trend toward increased disease-free interval in stage I patients, especially those with depressed immune responses.
Area of Science:
- Oncology
- Immunology
Background:
- Non-small cell lung cancer (NSCLC) is a leading cause of cancer mortality.
- Adjuvant therapy after surgical resection aims to improve outcomes.
- Immunotherapy has emerged as a promising treatment modality in various cancers.
Purpose of the Study:
- To evaluate the efficacy of Bacillus Calmette-Guérin (BCG) immunotherapy, alone or with allogeneic tumor cells, as an adjuvant treatment for resected stage I and II NSCLC.
- To investigate the correlation between immune status, assessed by mixed lymphocyte culture (MLC), and treatment response.
Main Methods:
- A randomized controlled trial involving 52 patients with stage I and II NSCLC post-resection.
- Patients were assigned to observation, BCG, or BCG plus allogeneic tumor cells.
- Disease-free interval (DFI) was the primary endpoint, with a mean follow-up of 39.5 months.
- Pre-treatment MLC values were assessed to gauge immune responsiveness.
Main Results:
- A trend towards an increased DFI was observed in stage I patients receiving immunotherapy (P = 0.088).
- Pre-existing depressed MLC values were noted in a subset of patients.
- Patients with depressed MLC values demonstrated a significant benefit in DFI when treated with immunotherapy.
Conclusions:
- Adjuvant immunotherapy with BCG may offer a survival benefit for select patients with early-stage NSCLC, particularly those with compromised immune function.
- Immune status assessment (MLC) could help identify patients most likely to benefit from immunotherapy.
- Further research is warranted to optimize immunotherapy strategies for NSCLC.